Terms: = Ovarian cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Prognosis
4 results:
1. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
[TBL] [Abstract] [Full Text] [Related]
2. Fibroblast growth factor receptor 4 (fgfr4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.
Heublein S; Anglesio MS; Marmé F; Kommoss S
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2251-2259. PubMed ID: 31385026
[TBL] [Abstract] [Full Text] [Related]
3. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract] [Full Text] [Related]
4. Fibroblast growth factor receptor 4 gene (fgfr4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
Marmé F; Hielscher T; Hug S; Bondong S; Zeillinger R; Castillo-Tong DC; Sehouli J; Braicu I; Vergote I; Isabella C; Mahner S; Ferschke I; Rom J; Sohn C; Schneeweiss A; Altevogt P
Int J Cancer; 2012 Aug; 131(4):E586-91. PubMed ID: 22034009
[TBL] [Abstract] [Full Text] [Related]
